Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Gemcitabine Pharmacokinetics After Preoperative Chemoradiation Therapy

Not Applicable

Terminated

Conditions: Pancreatic Cancer

Interventions: Drug: Gemcitabine

First Posted Date: 2013-09-10

Last Posted Date: 2020-11-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 12

Registration Number: NCT01938716

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Feasibility Study of Prophylactic White Blood Cell Transfusions

Phase 2

Completed

Conditions: Leukemia

Interventions: Procedure: White Blood Cell Transfusion

First Posted Date: 2013-08-30

Last Posted Date: 2018-01-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 45

Registration Number: NCT01932710

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)

Not Applicable

Terminated

Conditions: Myeloma

Interventions: Drug: Thalidomide
Drug: Lenalidomide
Behavioral: Questionnaires

First Posted Date: 2013-08-23

Last Posted Date: 2019-04-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT01927718

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Docetaxel
Other: Placebo
Drug: Erlotinib
Behavioral: Questionnaires
Behavioral: Phone Call
Drug: Chemotherapy

First Posted Date: 2013-08-23

Last Posted Date: 2025-01-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 55

Registration Number: NCT01927744

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant

Phase 2

Completed

Conditions: Bone Marrow Transplantation Recipient
Cord Blood Transplant Recipient
Hematopoietic Cell Transplantation Recipient

Interventions: Drug: Eltrombopag Olamine
Other: Laboratory Biomarker Analysis

First Posted Date: 2013-08-23

Last Posted Date: 2024-04-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 48

Registration Number: NCT01927731

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL), T-cell Lymphoma (TCL), and Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: Carfilzomib
Drug: Dexamethasone

First Posted Date: 2013-08-21

Last Posted Date: 2017-09-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT01926665

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)

Phase 2

Terminated

Conditions: Hematologic Disorder

Interventions: Drug: Lenalidomide
Biological: Influenza Vaccine
Biological: Pneumovax Vaccine

First Posted Date: 2013-08-16

Last Posted Date: 2018-09-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT01924169

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies

Phase 1

Completed

Conditions: B-Cell Non-Hodgkin Lymphoma
Hematopoietic and Lymphoid Cell Neoplasm
Leukemia
Lymphoma
Plasma Cell Myeloma
T-Cell Non-Hodgkin Lymphoma

Interventions: Biological: Ipilimumab
Drug: Lenalidomide

First Posted Date: 2013-08-09

Last Posted Date: 2024-12-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 41

Registration Number: NCT01919619

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Physical Activity in Promoting Smoking Cessation in African Americans

Not Applicable

Active, not recruiting

Conditions: Healthy Subject
Current Smoker

Interventions: Behavioral: Exercise Intervention
Other: Laboratory Biomarker Analysis
Drug: Nicotine Patch
Other: Questionnaire Administration
Other: Tobacco Cessation Counseling

First Posted Date: 2013-08-05

Last Posted Date: 2025-03-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 45

Registration Number: NCT01915810

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Prophylactic Salpingectomy With Delayed Oophorectomy

Not Applicable

Active, not recruiting

Conditions: Ovarian Carcinoma

Interventions: Procedure: Prophylactic Salpingectomy with Delayed Oophorectomy
Procedure: Risk-Reducing Salpingo-Oophorectomy
Other: Ovarian Cancer Screening
Behavioral: Questionnaire
Procedure: Transvaginal Ultrasound
Behavioral: Phone Call

First Posted Date: 2013-07-25

Last Posted Date: 2025-05-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT01907789

Locations: 🇺🇸
NorthShore University Health System, Evanston, Illinois, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy